At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. (Learn more). We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.
From our East Africa headquarters located in Nairobi, Kenya, for more than 60 years, Pfizer has been delivering life-changing breakthroughs to the people of Kenya and East Africa as a whole. Guided by our three pillars of innovation, investing and safeguarding, we work with Healthcare Practitioners, Policy Makers, Patient Groups and other members of civil society to serve the communities in which we live and work, broadening access to medicines and strengthening healthcare delivery for the people who need it most.
Living our values of courage, excellence, equity and joy, we are a diverse team of about 32 people working daily to provide all East Africans with access to global scientific innovation that can help them to live longer, better lives. Through our commitment to the national agenda, we are contributing to the development of a strong healthcare system, as well as growth of the knowledge economy in the interest of those who need to be empowered today and to the benefit of the generations to come.
Improving Access Through Innovation
To tackle the challenges of healthcare financing and access, we have partnered with Pharm Access to support the development and roll out of ‘M-Tiba’, a mobile health payment and savings platform for low income patients. As a result, 100,000 people in peri-urban Nairobi now have a financial subsidy to support them in accessing healthcare products and services for their children.
Antifungal Partnership Programme
We established the Antifungal Partnership programme to address associated fungal infections among people living with HIV. Since its inception, we have donated almost $1.5 billion dollars’ worth of medicine to 63 countries in the world including Kenya.
Investing In Diversity
Diversity makes us stronger. In support of societal transformation, we have committed ourselves to a journey of diversity and inclusion. We continually invest in our people and strive to ensure that our workforce is representative of the demographics of societies in which we operate. Nearly 60% of our Kenyan workforce is made up of women.
As part of our efforts to prevent blindness caused by Trachoma, our partnership with the International Trachoma Initiative has enabled us to donate over 18 million units of our Azithromycin antibiotic medication in Kenya, since 2006.
Investing In Healthcare Innovations
To aid the fight against infectious diseases, we launched, in 2016 the ‘Global Health Innovation Grants’ to directly support social enterprises and global health entrepreneurs in eight countries, including Kenya, to ensure healthcare delivery for difficult to reach and underserved populations. Over the last five years, approximately Ksh230 million has been invested in various projects partnering with non-profits and social entrepreneurs to support the development and scale-up of innovative health products & services for underserved individuals.
Investing In Anti-microbial Stewardship
Microbial resistance has been identified as one the biggest threats to public health. Investing in anti-microbial resistance is key to establishing a sustainable healthcare system. In response to this global threat, Pfizer has invested in ATLAS, a global data surveillance app that physicians around the world can use to look up regional patterns of resistance to antibiotics. Understanding these patterns of resistance enables doctors to stay abreast of trends in antibiotic resistance as they emerge and ensures that we are better equipped to protect future generations from AMR threats.
Our Values and Behaviours of Courage, Excellence, Equity and Joy are a declaration of our core beliefs and the defining features of a culture that drives achievement. They reflect the enduring character of Pfizer and its people.
“Culture is the most important thing we can get right.” – Albert Bourla, Pfizer Global Chairperson and CEO
At Pfizer, our purpose is to bring breakthrough’s that change patients’ lives. But breakthroughs are not only scientific; they are also logistical, technological and operational so we can deliver our breakthrough medicines and vaccines into more patients’ hands across the world even faster and to deliver on these breakthroughs requires a breakthrough mindset. It is for this reason that Pfizer has identified courage, excellence, equity and joy as its core values that will enable our purpose-driven growth strategy. Informed by these values our diverse team works daily to provide all Kenyans with access to global scientific innovation that can help them to live longer, better lives.
Breakthroughs start by challenging convention...especially in the face of uncertainty or adversity.
This happens when we think big, speak up and are decisive.
Every person deserves to be seen, heard and cared for.
This happens when we are inclusive, act with integrity, and reduce healthcare disparities.
We can only change patients' lives when we perform at our best together.
This happens when we focus on what matters agree who does what, and measure outcomes
We give ourselves to our work, and it also gives to us.
We find joy when we take pride, recognize one another, and have fun.
Pfizer’s purpose is to develop breakthroughs that change people’s lives. In the face of COVID-19, this call is more urgent than ever, and we have aimed to leave no stone unturned as we have harnessed the full breadth and depth of our resources to address this crisis.
During COVID-19 Pfizer’s actions have been guided by three priorities:
First, ensuring the safety and well-being of our colleagues;
Second, ensuring the continued supply of our medicines and vaccines to patients who need them across the world
Third, continuing our commitment to collaborate and play our part in discovering breakthrough therapies and vaccines to put an end to this pandemic.
In response to the pandemic, globally Pfizer has created a SWAT team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists and other key experts to focus solely on the discovery of an effective vaccine and/or a treatment to put an end to this pandemic.
Pfizer is committed to bringing this candidate vaccine to help meet the global public health need on an equitable basis. We are working closely with international initiatives, governments, and other stakeholders, as appropriate, to supply the world as quickly as we can, together. Alongside leading biopharmaceutical companies who are also conducting vaccine research and development, we’ve announced a historic pledge that outlines a united commitment to uphold the integrity of the scientific process as we work towards developing a potential vaccine for COVID-19 that puts patient safety and public health as top priorities.
With the global collaboration and unprecedented commitment to ending this pandemic we are confident that #sciencewillwin.